United States, August 2024 – Melissa Silen has joined Xenon Pharmaceuticals as the Vice President Human Resources, Commercial. In this role, Melissa will be responsible for leading HR initiatives across Xenon’s commercial operations, contributing to the company’s mission to improve the lives of patients suffering from debilitating neurological and psychiatric disorders.
Prior to joining Xenon Pharmaceuticals, Melissa served at Tripadvisor for over 6 years, where she held several key positions, including Vice President Human Resources, Tripadvisor Brand and Vice President Human Resources Global Commercial & Global Technology. During her tenure, she played a critical role in driving HR strategies that supported the company’s global operations and commercial success.
Before her time at Tripadvisor, Melissa worked at Biogen for over 4 years, where she was the Human Resources Business Leader for Global Supply Chain, PO&T Japan, and Asset Development. She also served as the Director, People and Organization Development for the company’s Pharmaceutical Operations and Technology division, where she contributed to significant HR initiatives and organizational growth.
Melissa’s extensive HR experience also includes roles at New Balance as Learning and Organization Development Manager, Genzyme as Leadership and Organization Development Consultant, and various HR and learning roles within Sanofi.
About Xenon Pharmaceuticals Inc.:
Xenon Pharmaceuticals (NASDAQ) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. The company is advancing a robust product pipeline to address unmet medical needs, particularly in epilepsy and depression. Xenon’s flagship program, azetukalner, is currently in Phase 3 clinical trials for epilepsy and is preparing for Phase 3 trials in major depressive disorder. The company’s discovery labs continue to leverage ion channel expertise to drive early-stage research and develop new therapeutic candidates.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
